Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Alimera Sciences

Biotech & Life Sciences · Alpharetta, United States · Founded 2003 · IPO 2010 Thoroughbred

Develops and commercializes prescription ophthalmic pharmaceuticals

Valuation
$360M
Market cap · 2026
Revenue
$105M
Latest reported FY
EBITDA
$6.8M
Latest reported FY

Investors

5 investors on Alimera Sciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage
Polaris Partners
Domain Associates
Scale Venture Partners
Intersouth Partners
Series B+ 1 investor entered at this stage

Global footprint

Where Alimera Sciences has talent and traffic

Workforce by country
16 countries with
team presence
🇺🇸 United States28.9%
🇬🇧 United Kingdom27.2%
🇵🇹 Portugal10.9%
🇩🇪 Germany10.1%
🇮🇪 Ireland3.6%
Top 5 of 16 shown
Web traffic by country
20 monthly visits
across markets
🇺🇸 United States0%
Top 1 markets shown

Market sentiment

What the market is saying about Alimera Sciences

An AI-synthesized read of the highest-engagement posts about Alimera Sciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Alimera Sciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.